Updated: ImprimisRx's Approval And Superiority Claims For Compounded Drug Draw FDA Warning
Executive Summary
The company known for compounding versions of Martin Shkreli’s Daraprim and Allergan’s Restasis is hit with a warning letter for promotions in professional periodicals about its compounded eye drop.
You may also be interested in...
Too Bold By Half: Allergan’s Latest Moves And Pharma’s Leadership Deficit
Allergan proudly describes itself as a 'bold' company, and its latest move to protect its Restasis franchise certainly qualifies as a reason why. But Allergan’s unlikely position as the industry’s self-appointed leader in social responsibility should make the rest of the industry cringe.
Turing’s Shkreli Tussels With Express Scripts About ‘Ugly, Dirty Truth’ Of Drug Pricing
Martin Shkreli says he will not lower price of antiparasitic Daraprim, noting shareholders want firm to make as much money as possible; he thanks Express Scripts’ CMO for not excluding the drug.
Companies Reveal Hurdles In Providing Drugs Via Expanded Access Programs
GSK, Stealth BioTherapeutics and Blueprint Medicines discuss the difficulties getting participation of physicians, the excessive cost of expanded access, and whether physicians should report research data.